Tirzepatide Shortage 2026: What Patients Need to Know
If you searched for "tirzepatide shortage" because you are having trouble filling your Mounjaro or Zepbound prescription, you are not alone. Millions of patients have navigated a confusing supply and
In this article
*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting, stopping, or changing any medication. Compounded medications from 503A pharmacies are not FDA-approved but are legally prepared by licensed compounding pharmacies.*
*Last updated: June 15, 2026. This page is updated regularly as the regulatory and supply situation evolves.*
---
If you searched for "tirzepatide shortage" because you are having trouble filling your Mounjaro or Zepbound prescription, you are not alone. Millions of patients have navigated a confusing supply and access landscape since tirzepatide exploded in demand following its 2023 approval for weight management.
Here is where things stand: the FDA officially removed tirzepatide from its drug shortage list in October 2024, and a federal court upheld that decision in May 2025. By the FDA's measure, supply has caught up with demand. But "shortage resolved" does not mean "easy to access." Insurance coverage gaps, cost barriers, and regional distribution issues mean many patients still struggle to get their medication.
This article covers the shortage history, what the official resolution means in practice, why access problems persist, and what your options are.
---
Is Tirzepatide Still in Shortage?
Officially, no. Tirzepatide was removed from the FDA's drug shortage database on October 2, 2024. Eli Lilly, the manufacturer of Mounjaro and Zepbound, has expanded manufacturing capacity significantly since the 2023 peak of the shortage. The FDA has maintained its position that commercial supply is sufficient to meet present and projected demand.
A federal district court in the Northern District of Texas upheld the FDA's shortage resolution on May 7, 2025, rejecting industry challenges that argued supply remained insufficient for certain dosages and patient populations. That decision settled the legal question of shortage status.
That said, "shortage resolved" and "widely accessible" are different things. Patients in some markets report difficulty obtaining specific doses, particularly higher-strength vials. Some pharmacies carry limited quantities. And the official shortage designation never addressed the largest access barrier: cost.
On the FDA shortage database today: Tirzepatide does not appear on the FDA's current shortage list. You can verify current status at the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/).
---
Why Tirzepatide Has Been Difficult to Access
Understanding the current access landscape requires understanding how tirzepatide's demand grew faster than anyone anticipated.
Unprecedented demand from weight loss approval. Tirzepatide was initially approved for type 2 diabetes management as Mounjaro in May 2022. When the FDA approved Zepbound for chronic weight management in November 2023, prescription volume surged. The SURMOUNT-1 trial had already demonstrated what patients and clinicians were eager to access: participants receiving tirzepatide 15mg once weekly lost an average of 20.9% of body weight over 72 weeks, compared to 3.1% in the placebo group (Jastreboff et al., *New England Journal of Medicine*, 2022, PMID: 35658024). No previous medication had achieved results at that scale.
Eli Lilly's manufacturing infrastructure was built for diabetes-scale demand. Weight management demand is categorically different, and the company's facilities were not ready for the volume.
Manufacturing scale-up challenges. Tirzepatide is a complex dual GIP/GLP-1 receptor agonist. Its synthesis and fill-finish manufacturing is more technically demanding than small-molecule drugs. Expanding capacity requires specialized equipment, regulatory site approvals, and multi-year lead times. Eli Lilly has invested billions in expanding production across its Indiana and North Carolina facilities, but that investment takes time to translate into pharmacy shelf availability.
Insurance coverage creating parallel demand. Most commercial insurance plans do not cover Zepbound (tirzepatide for weight management), even for patients with qualifying BMI and comorbidities. This created a parallel demand for compounded versions during the shortage period, as patients sought affordable access outside the commercial insurance system. That parallel market grew substantially during 2023 and 2024, adding demand pressure on top of already-strained commercial supply.
---
What to Do If Your Tirzepatide Is Out of Stock
If you are currently on Mounjaro or Zepbound and experiencing fill issues, here are the most practical steps.
Talk to your prescriber first. Before making any changes to your medication, contact the clinician who prescribed it. They can check regional availability, consider dose adjustments during supply gaps, and document your clinical history for continuity of care. Do not skip doses without guidance; your provider can help you manage a temporary supply gap safely.
Ask your pharmacy about alternative locations. Inventory varies significantly between pharmacy chains, independent pharmacies, and specialty pharmacies. Your prescriber or pharmacist may be able to identify locations with current stock, or help you transfer the prescription to a different dispensing pharmacy.
Ask about dose flexibility. Some patients experience fill issues with specific strengths, particularly during titration phases. Your prescriber may be able to identify whether a different strength could be temporarily appropriate, or whether your titration schedule can be safely adjusted.
Consider compounded tirzepatide from a licensed 503A pharmacy. During periods when supply or access is limited, licensed 503A compounding pharmacies can prepare tirzepatide for individual patients when a licensed prescriber documents a specific clinical reason. This is a legal, established option for appropriate candidates. The next section explains how this works.
---
Compounded Tirzepatide: A Legal, Available Alternative
Compounded tirzepatide is tirzepatide prepared by a licensed 503A compounding pharmacy based on an individual patient prescription. It is not FDA-approved as a finished product, but it is prepared by state-licensed compounding pharmacies under federal compounding law (21 U.S.C. § 503A) and regulated by state pharmacy boards.
The regulatory foundation. Prescriva's affiliated pharmacy partners are licensed 503A compounding pharmacies. Under 503A, a compounding pharmacy can prepare medications for individual patients when a licensed prescriber has documented a specific clinical need that the commercially available product does not meet. Examples of legitimate documented needs include:
- A documented allergy or hypersensitivity to an inactive ingredient in Mounjaro or Zepbound
- A requirement for a dosage strength not commercially available, such as a modified titration step
- A clinical determination that a different formulation is medically necessary for that specific patient
The active ingredient is the same. Both brand-name tirzepatide and compounded tirzepatide contain tirzepatide as the active pharmaceutical ingredient (API). The distinction is in how the finished product is made: Mounjaro and Zepbound undergo full FDA manufacturing review and approval; compounded tirzepatide does not. A licensed 503A pharmacy sourcing pharmaceutical-grade API from FDA-registered suppliers, following USP sterile compounding standards, and using appropriate cold chain distribution, provides meaningful quality assurance, though not the same as FDA approval of the finished product.
Cost comparison. Brand-name Mounjaro and Zepbound range from approximately $900 to $1,400 per month without insurance. Prescriva's compounded tirzepatide program is $259 per month, all-inclusive, covering the consultation, medication, and ongoing clinical oversight. For more detail, see [how much compounded tirzepatide costs](/resources/compounded-tirzepatide-cost-2026).
To understand the full picture of what compounded tirzepatide is and how it differs from the brand-name product, see the guide: [what is compounded tirzepatide](/resources/compounded-tirzepatide-guide).
---
---
What to Ask Your Provider
If you are considering switching from brand-name tirzepatide to a compounded version, or starting tirzepatide for the first time through a compounding pathway, these are the most important questions to have answered.
Ask about your documented clinical basis. What specific clinical reason will your provider document to support a compounded prescription? You are entitled to understand what is in your medical record.
Ask about the compounding pharmacy. Which pharmacy will prepare your medication? Is it licensed as a 503A facility? What is its source for tirzepatide API? Does it provide third-party testing documentation? A legitimate provider will answer these questions directly.
Ask about dose equivalency. If you are switching from brand-name tirzepatide to a compounded version at the same dose strength, ask your provider whether any adjustment is needed and what monitoring they recommend during the transition. For a guide on what to expect, see [switching GLP-1 medications](/resources/switching-semaglutide-to-tirzepatide).
Ask about ongoing oversight. A compliant telehealth program should include regular check-ins with a licensed provider, not just automated refills. Weight loss and metabolic management require clinical monitoring. Your prescriber should be reviewing your progress, not just generating renewal orders.
Ask about safety monitoring. Tirzepatide has a known but manageable side effect profile, with gastrointestinal symptoms being most common during dose escalation. Your provider should discuss what to expect and when to contact them. For a comprehensive review, see [tirzepatide safety profile](/resources/is-tirzepatide-safe).
---
Frequently Asked Questions
Is compounded tirzepatide the same as Mounjaro?
Both contain tirzepatide as the active ingredient, but they are not the same product. Mounjaro and Zepbound are FDA-approved finished products that have undergone full manufacturing review. Compounded tirzepatide is prepared by a state-licensed 503A compounding pharmacy based on a patient-specific prescription. It has not been reviewed or approved by the FDA as a finished product. Quality depends on the compounding pharmacy's practices rather than FDA approval of the final preparation.
Is compounded tirzepatide safe during a shortage?
The clinical data on tirzepatide's safety profile comes from studies of FDA-approved tirzepatide (Mounjaro and Zepbound), including the SURMOUNT-1 trial (PMID: 35658024) and SURMOUNT-2 trial (Garvey et al., *Lancet*, 2023, PMID: 37385275). That safety data reflects the branded formulation, not compounded versions. A compounded tirzepatide prepared by a licensed 503A pharmacy using pharmaceutical-grade API, under USP sterile compounding conditions, is made with the same active pharmaceutical ingredient (API). Compounded medications are not FDA-approved and have not been studied as finished products, which means quality assurance depends on the pharmacy's practices. Choosing a licensed, compliant pharmacy with third-party testing is the primary quality lever for patients. A licensed prescriber can help you evaluate whether the option is appropriate for your individual medical history.
Will the tirzepatide shortage end or return?
The FDA considers the tirzepatide shortage resolved as of October 2024. Eli Lilly has substantially expanded manufacturing capacity and continues investing in additional production facilities. A return to shortage status would require a significant and sustained mismatch between commercial supply and demand, which the FDA would need to formally determine and list.
Why does supply still feel tight if the shortage is resolved?
Official shortage resolution reflects FDA's assessment of overall supply versus demand at the national level. Local and regional distribution can still be uneven. Specific dose strengths may have lower availability in some markets. And the primary access barrier for most patients remains cost, not physical supply: Mounjaro and Zepbound remain among the most expensive medications on the U.S. market without insurance coverage.
Does Eli Lilly offer any patient assistance for Mounjaro or Zepbound?
Yes. Eli Lilly's Lilly Cares Foundation offers assistance programs for qualifying patients, and Lilly offers savings cards for commercially insured patients. Eligibility requirements and program terms vary. Contact Eli Lilly directly or visit their patient assistance resources for current program details.
---
What's Next for Tirzepatide Access
Eli Lilly has announced continued manufacturing investment and expects to sustain current supply levels through 2026 and beyond. Several analysts project that expanded capacity will gradually improve regional availability and reduce the distribution variability patients have experienced.
The longer-term access picture depends heavily on insurance coverage decisions. As clinical evidence continues to accumulate including the SURMOUNT trials' cardiovascular and metabolic data, more payers are evaluating coverage of GLP-1 medications for weight management. Coverage expansion, if it materializes meaningfully, would be the most significant change to the access equation.
In the interim, compounded tirzepatide through a licensed 503A pharmacy remains a legal and cost-accessible option for qualifying patients.
---
Starting or Continuing Tirzepatide Treatment
If you are struggling with access to brand-name tirzepatide, a clinical evaluation is the right first step. Prescriva connects you with independently licensed healthcare providers who can review your history, assess whether a compounded tirzepatide prescription is appropriate for your individual situation, and connect you with a licensed 503A pharmacy partner operating in compliance with current regulations.
Prescriva is a telehealth management services organization. Your prescription would be filled by a licensed 503A compounding pharmacy in our affiliated network. Compounded tirzepatide is not FDA-approved.
[Check your eligibility](/start) (no commitment required).
Or keep reading:
- [What Is Compounded Tirzepatide? A Plain-Language Guide](/resources/compounded-tirzepatide-guide)
- [How Much Does Compounded Tirzepatide Cost in 2026?](/resources/compounded-tirzepatide-cost-2026)
- [Switching from Semaglutide to Tirzepatide](/resources/switching-semaglutide-to-tirzepatide)
- [Is Tirzepatide Safe?](/resources/is-tirzepatide-safe)
*Sources and further reading:*
- *[FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/)*
- *Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.*
- *Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275.*
- *21 U.S.C. § 503A: Pharmacy Compounding.*
Stay informed
Weekly research updates and health guides. No spam.
Ready to get started?
Check if you qualify for a personalized treatment plan.
Check Your Eligibility →
